Feed aggregator

Whole Kids Foundation School Garden Grant

ScanGrants - Nutrition -

Whole Kids Foundation School Garden Grant

October 31st at 5pm CST (6pm EST, 4pm MST, 3pm PST): Application closes.

Eligibility criteria:

1. School garden must be an edible school garden (such as growing fruits, vegetables, herbs, grains, etc) and located on the grounds of a K-12 school (public, private or charter, elementary, middle or secondary)

2. Applicant must be a nonprofit K-12 school (public, private or charter, elementary, middle or high) or a 501(c)(3) nonprofit organization working in partnership with a K-12 school.

3. Applicant cannot be a previous recipient of a Whole Kids Foundation School Garden Grant.

4. Applicant must have the participation and support of a specific partner organization from the community (such as a nonprofit, a farm, a local business, a Whole Foods store, or a garden club) that brings added support and sustainability to the initiative. The applicant, if a nonprofit, may be the community partner for this grant.

Have questions? Contact gardens@wholekidsfoundation.org!

Call for Nominations: 2016 Society for Adolescent Health and Medicine/Iris F. Litt Visiting Professorship in Adolescent Health Research

ScanGrants - Nutrition -

Call for Nominations: 2016 Society for Adolescent Health and Medicine/Iris F. Litt Visiting Professorship in Adolescent Health Research

The Society for Adolescent Health and Medicine Visiting Professorship in Adolescent Research was established in 1995 with the first award being given for 1995. The intent of this award was to provide an educational experience in Adolescent Research for a group of health care providers and researchers who might not otherwise have the opportunity to benefit from the professor’s expertise.

In 2005, the Board of Directors named this professorship in perpetuity to honor Dr. Iris F. Litt because of her substantial contributions to the field of adolescent medicine and adolescent health, as well as her tenure as the Editor-in-Chief of the Journal of Adolescent Health. In addition, the Board of Directors modified the title of this award to make it more consistent with the mission and purpose of this educational activity.

CRITERIA: The Visiting Professorship Program is intended to help clinical, research, policy and training programs that are currently engaged in clinical care of adolescents, research or policy to improve the research components to become better equipped to conduct adolescent health-focused research as well as to improve the ability of the researchers to successfully compete for funding a research program. Consultation from the visiting professor is not a substitution for an institution’s commitment to providing needed resources.

Ideally the award will be made to programs that provide advanced training in medicine, psychology, social work, nursing, nutrition, or public health programs that focus on adolescent health which can demonstrate that the visiting professorship program will enhance the research capacity of trainees, graduate or post-graduate students, faculty, and other health professionals who serve adolescents. Candidates to be considered for this Award may or may not be members of the Society for Adolescent Health and Medicine.

SELECTION PROCESS: Nominations for both the Visiting Professor and the host site are accepted from any current member of SAHM. The SAHM Awards: Research Sub-Committee is charged with selecting both the Visiting Professor and host site.

BUDGET AND ADMINISTRATION: The award is financially administered through the Society's business office. The Award includes an engraved plaque, an honorarium of $2,000, with travel expenses for award recipients reimbursed with receipts up to $1,500. The host site awarded the professorship must agree to assume responsibility for travel expenses that exceed $1,500.

DEADLINE: Applications for the 2016 SAHM/ Iris F. Litt  must be received electronically to ccody@adolescenthealth.org by no later than October 28th, 2014. The winner will be notified in January 2015  and award funds will be distributed at the SAHM Annual Meeting in Los Angeles on March 18, 2015.

The JDRF and the Helmsley Charitable Trust Request Expressions of Interest for Improved Assays for Predicting Risk for T1D

ScanGrants - Diabetes -

The JDRF and the Helmsley Charitable Trust Request Expressions of Interest for Improved Assays for Predicting Risk for T1D

JDRF and The Leona M. and Harry B. Helmlsey Charitable Trust are soliciting expressions of interest (EOI) for optimizing and validating existing technologies for predictive screening for T1D risk and autoimmunity to be applied for wide-spread use in population-based screening efforts, including newborn or childhood based screening. EOIs requesting development of new assays will not be considered.

BACKGROUND

Prevention of type 1 diabetes (T1D) represents a “cure” for those at-risk of developing the disease, and, in fact, will likely represent the most cost-effective approach to a cure and is becoming increasingly important with the rising incidence of the disease. Over the last three to four decades, the incidence of T1D has increased at an annual rate of 3-5% with penetration to low-moderate human leukocyte antigen (HLA) risk groups, suggesting a lowered threshold for its development. In some countries, the largest increase in incidence has occurred in the age group 1-5 years.

Currently, assays of islet autoantibodies (AAb) are the most robust approach to detect risk in relatives of individuals with T1D and aid in predicting progression to T1D in HLA at-risk children. Indeed , the 10-year risk of progression to symptomatic T1D with multiple islet AAbs (insulin, GAD65, IA-2 and ZnT8) is 70%. However, the current practices for AAb screening, including screening for genetic risk in neonates or screening for AAb first-degree or second-degree relatives who are known to have an increased risk, detect only 40% and 15% respectively of individuals who will progress to T1D. Only a relatively small proportion of HLA at-risk children develop T1D.

Therefore, new approaches are required to increase sensitivity and specificity of screening. Existing AAb protocols to predict risk of T1D are also costprohibitive for universal childhood screening.

Efforts are underway to better predict risk of development of autoimmunity and the earliest stages of autoimmunity using metabolomics, microbiome metagenomics, transcriptomics, and T-cell assays.

Furthermore, there are ongoing efforts to integrate and model diverse data (genetic, immunologic, metabolic, age, etc.) to develop composite predictive risk scores that better predict rate of progression.

The development of technologies to improve T1D risk detection in the general population would facilitate recruitment for clinical research focused on identifying environmental triggers and natural history of T1D, along with interventions to prevent T1D.

OBJECTIVES

Expressions of interest are sought from investigators who seek to optimize and/or validate existing platforms for use in predicting risk of T1D, both prior to and after development of AAbs. These assays should meet the following criteria for general population-based screening, which may include newborn or childhood-based screening methods:

a. Selectivity, sensitivity, ease of use

b. High-throughput capacity

c. Low volume needed

d. Low cost

e. Possibility for the assay to be deployed as point-of-care testing

Investigators with ideas or resources that might benefit this initiative should also submit their ideas via an expression of interest.

This EOI will not support the development of new technologies or assays.

ELIGIBILITY

Applicants must hold an M.D., D.M.D., D.V.M., Ph.D., or equivalent academic degree and a faculty position or equivalent at a college, university, medical school, for-profit research based organization or other comparable institution.

Applications may be submitted by domestic or foreign public or private non-profit organizations, such as colleges, universities, hospitals, laboratories, units of state or local governments or eligible agencies of the federal government.

Please note that applications from for-profit entities or industry collaborations with academia may be submitted to this EOI, however, additional information will be requested from for-profitentities if a full application is invited.

There are no citizenship requirements.

MECHANISM

EOIs in response to this announcement can be submitted to the following mechanism:

Strategic Research Agreements (supported by strong feasibility data) for a maximum budget of $200,000 per year for up to 2 years of funding (including 10% indirect costs).

Applications that are not funded in this competition may be resubmitted to other JDRF grant mechanisms according to the deadlines and guidelines described on the JDRF Web site: http://www.jdrf.org/

DEADLINES

-- Expression of Interest: September 22, 2014 (5:00pm, Eastern Time)

-- EOI Notification: October 1, 2014

-- Application Due Date: October 31, 2014 (5:00pm, Eastern Time)

-- Response to Applicants Date:  January 2015

-- Earliest Anticipated Start Date: February 2015

EOI COMPONENTS

Prospective applicants should submit an expression of interest on-line via RMS360 at
https://jdrf.smartsimple.us The EOI template located under the LOI Research Plan tab must be used to
submit.

EOI submissions will undergo expedited review. Applicants will be notified if they have been approved to submit a full application.

JDRF Requests Expressions of Interest for Studies Relevant to the Discovery and Development of Antigen Specific Therapies for Human Type 1 Diabetes

ScanGrants - Diabetes -

JDRF Requests Expressions of Interest for Studies Relevant to the Discovery and Development of Antigen Specific Therapies for Human Type 1 Diabetes

Key Dates:

August 15, 2014: Expressions of interest (EOI) release date

October 10, 2014: EOI due date

October 31, 2014: EOI decision notification

December 10, 2014: Full application due date (for accepted EOIs)

April 2015: Award notification May 2015: Earliest start date

Purpose of Request

JDRF is soliciting expressions of interest (EOI) for the discovery, development, pre-clinical or pilot clinical testing of novel antigen-specific therapeutic approaches designed to induce durable immunoregulation for human type 1 diabetes (T1D). JDRF is committed to translation of research findings towards clinical results and is most interested in projects that have clinical translation potential.

Background

Immunotherapeutic approaches for preventing or halting T1D have involved both antigen-specific and antigen non-specific interventions. Because T1D results from a failure to maintain immune tolerance to islet antigens/autoantigens, targeting the immune response to these antigens/autoantigens may provide an effective means of preventing and controlling the autoimmune response and avoid the harmful effects associated with non-specific immunosuppression. Clinical data from several independent trials has provided compelling evidence that current immunomodulatory approaches are not optimally effective at preventing T1D or at durably controlling beta cell loss in the recent onset T1D setting. In addition, islet transplantation trials show recurrence of beta cell antigen specific autoreactivity under the cover of immunosuppressive therapy.

Specific Goals of Request

Expressions of interest are sought from investigators interested in discovering and developing, or in evaluating in pre-clinical models or pilot clinical studies, novel antigen-specific therapies for T1D. Such therapies may have application for: 1) the at-risk, immunologically unprimed setting with primary prevention of T1D and/or for the immunologically primed setting with secondary prevention of T1D; 2) for control of autoimmunity in the new onset T1D setting; or 3) in combination with other immunomodulatory therapies or approaches to robustly induce immunoregulation and regenerate beta cells to restore insulin independence in the recent onset and established T1D setting. The clinical translation potential of the investigations should be emphasized. Of interest are also mechanistic studies and biomarker discovery/validation around antigen-specific T1D clinical trials.

Examples of pertinent topics include, but are not limited to:

-- Discovery of novel antigen-specific therapies for T1D

-- Validate and further develop existing antigen-specific approaches to enable and accelerate their clinical translation

-- Dose finding studies, differences in unprimed vs. primed autoimmune responses, optimization of treatment regimens, and in silico modeling

-- Elucidate mechanisms of action of antigen-specific approaches to improve efficacy and refine the therapeutic strategy.

-- Mechanistic studies for ongoing or recently completed antigen-specific clinical trials in T1D

-- Pilot clinical trials of antigen-specific efficacy using a single agent or combination agents as measured by short-term mechanistic endpoints that reflect robust immune-regulation. Please note that JDRF recently released an EOI for Combination Therapies in Type 1 Diabetes. This EOI is not meant as a replication of that EOI, and EOIs that were submitted to that mechanism will not be considered here.

-- Investigators with ideas or resources that might benefit this initiative should also submit their ideas via an expression of interest.

Levels of Funding and Grant Mechanisms:

Applications in response to this announcement can be submitted under one of the following three funding mechanisms:

-- Innovative Grants: up to $110,000 (including 10% indirect costs) for one year only.

-- Strategic Research Agreements (SRAs): up to $250,000/yr (including 10% indirect costs) for up to two years.

For any research projects proposed for 3 years, applicants must contact JDRF to discuss its scientific justification. For any budget that exceeds $250,000/yr, JDRF scientific staff must be contacted with a strong justification, prior to EOI submission. SRAs require quarterly milestones, reporting against those milestones and will receive milestone-based payments.

-- Clinical grants for pilot trials: up to $1,000,000 total costs (including 10% indirect costs) for a maximum of 3 years. For any trials proposed for greater than 3 years or for a larger budget, JDRF scientific staff must be contacted prior to EOI submission. Clinical awards require pre-established milestones and will receive milestone-based payments.

-- For all submissions, proposed budgets should be well-justified and commensurate with the type of study and the research plan.

Transforming Prediabetes Care Initiative: A National Demonstration for Free and Charitable Clinics

RAC - Health Promotion and Disease Prevention -

Awards funding and technical support to participate in the Transforming Prediabetes Care Initiative, which will work to build the readiness of free andcharitable clinics to address chronic disease through prevention, adoption of technology and implementation of evidence-based interventions. Geographic coverage: Nationwide -- AmeriCares

Verizon Foundation Grant Program

ScanGrants - Diabetes -

Verizon Foundation Grant Program

The Verizon Foundation’s primary philanthropic focus areas are: Healthcare for children, women and seniors; STEM education for K-12 youth and Energy Management. Grant applications are by invitation only and are reviewed from February 3, 2014 through midnight on October 10, 2014. Please contact your local Verizon Community Relations Manager to learn more.

Healthcare-related Programs

Verizon Foundation is leveraging its technology and resources to improve quality and access for children, women and seniors in rural and urban communities in need. Our main focus is to reduce healthcare disparities, improve access and quality, and enable better chronic disease outcomes through health information technology that educates and empowers patients to self-manage their health.

Improving Access for Children

We use technology to connect children to better healthcare, reducing the impact of chronic disease in our most vulnerable communities. We partner with innovative organizations who aim to reduce the impact and disparities of obesity, diabetes & asthma as chronic conditions through technology to help kids get and stay healthy

Empowering Health for Women

Due to a lack of regular access to care along with other factors, women are frequently diagnosed later with chronic diseases than men, and experience higher fatality rates. That is why we support partnerships that highlight the role technology can play in in increasing access  to care and chronic disease management for underserved women.

Connecting Health for Seniors

We connect healthcare providers, patients and care-givers to create innovative care models, enabling seniors with chronic disease to age in place.  We support the work of our partners nationwide in this endeavor.

Domestic Violence Prevention

We invest in organizations that provide education, prevention, care for victims and empowerment resources.

Verizon Foundation Grant Program

ScanGrants - Obesity -

Verizon Foundation Grant Program

The Verizon Foundation’s primary philanthropic focus areas are: Healthcare for children, women and seniors; STEM education for K-12 youth and Energy Management. Grant applications are by invitation only and are reviewed from February 3, 2014 through midnight on October 10, 2014. Please contact your local Verizon Community Relations Manager to learn more.

Healthcare-related Programs

Verizon Foundation is leveraging its technology and resources to improve quality and access for children, women and seniors in rural and urban communities in need. Our main focus is to reduce healthcare disparities, improve access and quality, and enable better chronic disease outcomes through health information technology that educates and empowers patients to self-manage their health.

Improving Access for Children

We use technology to connect children to better healthcare, reducing the impact of chronic disease in our most vulnerable communities. We partner with innovative organizations who aim to reduce the impact and disparities of obesity, diabetes & asthma as chronic conditions through technology to help kids get and stay healthy

Empowering Health for Women

Due to a lack of regular access to care along with other factors, women are frequently diagnosed later with chronic diseases than men, and experience higher fatality rates. That is why we support partnerships that highlight the role technology can play in in increasing access  to care and chronic disease management for underserved women.

Connecting Health for Seniors

We connect healthcare providers, patients and care-givers to create innovative care models, enabling seniors with chronic disease to age in place.  We support the work of our partners nationwide in this endeavor.

Domestic Violence Prevention

We invest in organizations that provide education, prevention, care for victims and empowerment resources.

UltraEcho, Ltd. Cardiovascular Student Travel Grant

ScanGrants - Cardiovascular -

UltraEcho, Ltd. Cardiovascular Student Travel Grant

The American Society of Echocardiography Education and Research Foundation (ASEF) is pleased to announce the availability of a travel grant for a sonography student enrolled in an accredited CAAHEP cardiovascular ultrasound program.  The travel grant program is designed to provide partial financial support to a sonography student who would otherwise be unable to attend the ASE 26th Annual Scientific Sessions in Boston, MA, June 13-16, 2015, or any other 2015 educational courses directly sponsored by ASE.  A complimentary registration fee is included with the travel grant award, along with a one year student membership in the American Society of Echocardiography.

This travel grant is based on financial need.ASEF thanks UltraEcho, Ltd. for sponsoring this annual student travel grant.

Award Amount  $1,000.00

Application Receipt Deadline:  November 30, 2014

Award Announcement:  February 2015

Award Payment Date:  February 2015

To Apply:

*  Complete the on-line UltraEcho, Ltd. Cardiovascular Sonographer Student Travel Grant form.

Criteria for Award:

*  Students must be actively enrolled in  cardiovascular ultrasound programs accredited by the commission on Accreditation of Allied Health Education Programs (CAAHEP) or in equivalent Canadian or international cardiovascular ultrasound programs* at the time of the grant selection.  Students graduating in the Spring/Summer of 2015 are eligible to apply.

*   International candidates will need to submit information describing equivalency of program to CAAHEP standards and/or course work that follows the National Education Curriculum (NEC).

*  This travel grant is based on financial need.  While any sonography student actively enrolled in a CAAHEP cardiovascular program may apply for this travel support, the selection process will give preference to students without sufficient travel funding and who would not otherwise be able to attend an educational course directly sponsored by ASE.  If selected to receive an ASEF student travel grant, the student will be requested to provide a written testimonial and personal photo for use in promotional materials and/or on ASEF’s website.

Students who are nominated for an Alan D. Waggoner Student Scholarship Award may also apply for the UltraEcho, Ltd. Cardiovascular Student Travel Grant and the Feigenbaum Student Travel grant; however, a student will only be selected for one award.

Pages

Subscribe to PlantBasedResearch aggregator